References
- World Health Organization. Global tuberculosis report 2019. 2019. p. 283. https://www.who.int/publications/i/item/9789241565714
- Global tuberculosis report 2018 [Internet]; [cited 2022 Oct 12]. Available from: https://apps.who.int/iris/handle/10665/274453
- Song L, Wu X. Development of efflux pump inhibitors in antituberculosis therapy. Int J Antimicrob Agents. 2016;47(6):421–429. https://pubmed.ncbi.nlm.nih.gov/27211826/
- Rossi E D, Aínsa JA, Riccardi G. Role of mycobacterial efflux transporters in drug resistance: an unresolved question. FEMS Microbiol Rev. 2006;30(1):36–52. https://pubmed.ncbi.nlm.nih.gov/16438679/
- Brennan PJ. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinb). 2003;83(1-3):91–97. https://pubmed.ncbi.nlm.nih.gov/12758196/
- Microbial efflux pumps: current research [Internet]; [cited 2022 Oct 12]. Available from: https://www.caister.com/efflux-pumps
- McKeegan KS, Borges-Walmsley MI, Walmsley AR. The structure and function of drug pumps: an update. Trends Microbiol. 2003;11(1):21–29. https://pubmed.ncbi.nlm.nih.gov/12526851/
- Pasca MR, Guglierame P, Arcesi F, et al. Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2004;48(8):3175–3178. https://pubmed.ncbi.nlm.nih.gov/15273144/
- Li XZ, Zhang L, Nikaido H. Efflux pump-mediated ıntrinsic drug resistance in Mycobacterium smegmatis. Antimicrob Agents Chemother. 2004;48(7):2415–2423.
- Sun Z, Xu Y, Sun Y, et al. Ofloxacin resistance in Mycobacterium tuberculosis is associated with efflux pump activity independent of resistance pattern and genotype. Microb Drug Resist. 2014;20(6):525–532. https://pubmed.ncbi.nlm.nih.gov/24940805/
- Martins M, Schelz Z, Martins A, et al. In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis. Int J Antimicrob Agents. 2007;29(3):338–340.
- M24Ed3 | Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes, 3rd ed. [Internet]; [cited 2022 Oct 12]. Available from https://clsi.org/standards/products/microbiology/documents/m24/
- Coban AY, Akbal AU, Uzun M, et al. Evaluation of four colourimetric susceptibility tests for the rapid detection of multidrug-resistant Mycobacterium tuberculosis isolates. Mem Inst Oswaldo Cruz. 2015;110(5):649–654. https://pubmed.ncbi.nlm.nih.gov/26222021/
- Calgin MK, Sahin F, Turegun B, et al. Expression analysis of efflux pump genes among drug-susceptible and multidrug-resistant Mycobacterium tuberculosis clinical isolates and reference strains. Diagn Microbiol Infect Dis. 2013;76(3):291–297. https://pubmed.ncbi.nlm.nih.gov/23561272/
- Huang TS, Kunin CM, Wang HM, et al. Inhibition of the Mycobacterium tuberculosis reserpine-sensitive efflux pump augments intracellular concentrations of ciprofloxacin and enhances susceptibility of some clinical isolates. J Formos Med Assoc. 2013;112(12):789–794. https://pubmed.ncbi.nlm.nih.gov/24331109/
- Escribano I, Rodríguez JC, Llorca B, et al. Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid. Chemotherapy. 2007;53(6):397–401. https://pubmed.ncbi.nlm.nih.gov/17934259/
- Singh M, Jadaun GPS, Ramdas, Srivastava K, et al. Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates. Indian J Med Res. 2011;133(5):535–540.
- Spies FS, Almeida Da Silva PE, Ribeiro MO, et al. Identification of mutations related to streptomycin resistance in clinical ısolates of Mycobacterium tuberculosis and possible ınvolvement of efflux mechanism. Antimicrob Agents Chemother. 2008;52(8):2947–2949.
- Li G, Zhang J, Guo Q, et al. Efflux pump gene expression in multidrug-resistant Mycobacterium tuberculosis clinical ısolates. PLoS One. 2015;10(2):e0119013. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0119013